Danaher Corporation $DHR Holdings Decreased by Steward Partners Investment Advisory LLC

by · The Cerbat Gem

Steward Partners Investment Advisory LLC reduced its holdings in Danaher Corporation (NYSE:DHR – Free Report) by 16.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,186 shares of the conglomerate’s stock after selling 3,414 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Danaher were worth $3,395,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of DHR. White Pine Capital LLC increased its holdings in shares of Danaher by 1.4% in the 2nd quarter. White Pine Capital LLC now owns 3,494 shares of the conglomerate’s stock valued at $690,000 after purchasing an additional 49 shares during the period. Boyd Watterson Asset Management LLC OH increased its stake in Danaher by 2.1% in the 2nd quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock valued at $499,000 after buying an additional 51 shares during the period. Worth Financial Advisory Group LLC lifted its position in Danaher by 4.6% in the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock worth $236,000 after buying an additional 53 shares in the last quarter. 1834 Investment Advisors Co. lifted its position in Danaher by 3.3% in the 1st quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate’s stock worth $342,000 after buying an additional 54 shares in the last quarter. Finally, Bruce G. Allen Investments LLC boosted its stake in shares of Danaher by 13.1% during the 2nd quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock valued at $92,000 after buying an additional 54 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 21,776 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the sale, the senior vice president directly owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. This trade represents a 59.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Teri List sold 3,298 shares of Danaher stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total value of $746,997.00. Following the completion of the transaction, the director owned 20,762 shares in the company, valued at $4,702,593. The trade was a 13.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 30,248 shares of company stock worth $6,609,663 over the last ninety days. Company insiders own 11.10% of the company’s stock.

Danaher Stock Down 1.0%

DHR opened at $228.41 on Friday. The firm has a market cap of $161.33 billion, a P/E ratio of 47.09, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The business has a 50 day moving average price of $211.54 and a 200 day moving average price of $202.99. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $258.23.

Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter last year, the firm posted $1.71 earnings per share. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. Research analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were given a dividend of $0.32 per share. The ex-dividend date of this dividend was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s payout ratio is currently 26.39%.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on DHR. Royal Bank Of Canada set a $241.00 price objective on Danaher in a report on Tuesday, September 2nd. Wells Fargo & Company reaffirmed a “positive” rating on shares of Danaher in a research note on Thursday, October 23rd. Evercore ISI lifted their price target on Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. Deutsche Bank Aktiengesellschaft increased their price objective on Danaher from $235.00 to $250.00 and gave the stock a “buy” rating in a report on Wednesday, October 22nd. Finally, Rothschild & Co Redburn reiterated a “neutral” rating and issued a $220.00 target price (down from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. Eighteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $243.39.

View Our Latest Report on Danaher

Danaher Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Further Reading

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).